On Site Poster Sessions

POSTERS SESSIONS On–site information

The Strolling Poster sessions, take place during the following slots:

  • July 15th 2025 from 17.30 to 19.00
  • July 16th 2025 from 18.00 to 19.00

Posters are located in Poster Area inside the Boulevard Room (Boulevard Level). Poster Presenters must attend for the whole duration of their session. It’s mandatory to respect the timing as detailed in the following scheme.
Each poster presenter will be given 3 minutes to introduce the scientific paper, followed by a short discussion with the chairs. Posters are listed below alphabetically accordingly to first author. On each panel on-site you will find the Poster # as listed here. Please respect the poster # indications when you hang posters.

We kindly remind you that Rising Stars and Oral Presenters are requested to prepare and display the poster on posters panel. No discussion is scheduled for these categories during the Strolling Poster Sessions.

 

Tuesday, 15th July 2025 from 17.30 to 19.00

Session 1: Basic Science

Chairs: W. Jin-fu (China) – Steven Taylor (USA)

×
Search :
#PresenterFirst AuthorDayAbs #Title
1Benjamin DigginsBenjamin Diggins001Anti-inflammatory and clinical effects of oral resveratrol supplementation in bronchiectasis
2Masaki FujitaMasaki Fujita002Possible animal model of bronchiectasis? Chronic Pseudomonas aeruginosa infection provoked enlargement of small bronchus lumen in CCSP-deficient mice.
3Rebecca HullRebecca Hull003Targeted Multiplex PCR for Characterising Infection Dynamics in Bronchiectasis
4Geonhui MinGeonhui Min004Exploring Immune Dysfunction in Bronchiectasis: A Focus on Natural Killer Cells using Single-Cell Transcriptomes
5Patricia NamubiruPatricia Namubiru005Functional and phenotypic neutrophil characteristics in bronchiectasis in adult humans.
6Shital Vishnu PatilShital Vishnu Patil006Microbiological and Pathophysiological Profile in Cases with Recurrent Exacerbation of Bronchiectasis: A Two-Center Experience
7Craig SchofieldCraig Schofield007A single cell RNA sequencing pipeline to assess airway inflammation using induced sputum samples from a prospective cohort of children with bronchiectasis
8Xiyue ShenXiyue Shen008First Nationwide Screening of Cystic Fibrosis Among Chinese Bronchiectasis Patients: Distinct Clinical and Genetic Profiles with Therapeutic Implications.
9Hans Van der WallHans Van der Wall009Strong correlations between location of Bronchiectasis and scintigraphic sites of lobar pulmonary micro-aspiration of gastoesophageal refluxate
10Yimin ZhuYimin Zhu010Profiling DPP-1 signalling networks underlying lung immune defence

 
 

Session 2: Comorbidities & Difficult Cases

Chairs: W. Basil (Switzerland) – Yong.hua Gao (China)

Search :
#PresenterFirst AuthorDayAbs #Title
1William FlowersHarriet Caterson011Unmasking disease in ulcerative colitis-associated bronchiectasis after treatment with vedolizumab
2Shital PatilShital Patil012Role of nebulised amikacin as an â€adjunct’ to standard care in recurrent exacerbation Bronchiectasis during acute care hospitalization and follow-up period of 52 weeks: A two-tertiary care center study
3Louis ChaiLouis Chai013Bronchiectasis and Recurrent Infections in Thymoma Patients Attributable to Anti-Cytokine Autoantibodies
4William GoodWilliam Good014Are we missing sinus disease in bronchiectasis? A sub-study of the Bactek-O trial.
5Dawkins PaulJeremy Ishi015How do comorbidities affect outcomes in the New Zealand bronchiectasis population?
6Christine LuChristine Lu016Routine pathology testing prior to bronchoscopy: Limited clinical impact with significant economic and environmental costs
7Dilara O.TopcuDilara O.Topcu017Impact of the February 6,2023 Earthquake-Induced Environmental Pollution on Exacerbation Rates in Patients with Bronchiectasis
8Shital PatilShital Patil018Clinical Benefit Analysis of Erdosteine plus azithromycin in comparsion to standard care in preventing exacerbation in recovered cases of acute exacerbation of Bronchiectasis: A long-term Comparative Efficacy Study
9Kirsty WatsonKirsty Watson019The treatable traits approach is highly acceptable and a positive experience for patients in a regional Australian bronchiectasis outpatient clinic

 
 

Session 3: Diversity

Chairs: Lucy Burr(Australia) – Charles Feldman (South Africa)

Search :
#PresenterFirst AuthorDayAbs #Title
1Shereen Sharafaddin AlemamShereen Sharafaddin Alemam020Chronic Bronchiectasis Complicated by Common Variable Immunodeficiency (CVID): A Case Study of Multidisciplinary Management"
2Eleni BacopanosEleni Bacopanos021Morbidity and mortality burden from bronchiectasis in the United Kingdom: An observational cohort study
3Subash HeraganahallyDayna Duncan022A clinical approach to the diagnosis and management of Bronchiectasis in adult Aboriginal patients in the Top End Northern Territory Australia
4Heraganahally SubashDayna Duncan023Bronchiectasis Pocket Guide
5Jamie R. FelzerJamie R. Felzer024Sociodemographic Factors Associated with Health Outcomes in a Sample of the U.S. Bronchiectasis and Nontuberculous Mycobacteria Research Registry
6Timothy HowarthTimothy Howarth025The Indigenous Bronchiectasis Assessment Scale - IBAS
7Shereen Sharafaddin AlemamShereen Sharafaddin Alemam026Comprehensive Diagnostic and Management Approach in a Case of Bilateral Bronchiectasis with Hemoptysis in a Heavy Smoker
8Eleni BacopanosEleni Bacopanos027Bronchiectasis mortality trends across Europe between 2011 – 2018.
9Weijie GuanMingxin Shi028Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis

 
 

Session 4: Epidemiology & Registries

Chairs: Pamela J. McShane (USA) – Raja Dhar (India)

Search :
#PresenterFirst AuthorDayAbs #Title
1Jacob ChristensenJacob Christensen029Sunshine Coast Hospital and Health Service Bronchiectasis Registry: First local insights into an increasing healthcare burden
2Alexander GeyerAlexander Geyer030Reproductive Lifespan and Post-menopausal Bronchiectasis in U.S. Postmenopausal Women: An investigation of the Women’s Health Initiative Cohort
3George SolomonEmily Henkle031Treatment patterns by exacerbation history in adults with bronchiectasis: data from the U.S. Bronchiectasis and NTM Research Registry
4Doreen Addrizzo-HarrisChristina Hunt032U.S. BRONCHIECTASIS AND NTM CARE CENTER NETWORK: Improving the Diagnosis and Treatment of Bronchiectasis and Nontuberculous Mycobacterial Lung Disease
5Eunchae KimEunchae Kim033Tailored AI Model for the Prediction of Severe Acute Exacerbation in an Asian
6Jack RobertsJack Roberts034Medicare and Pharmaceutical Benefit Scheme utilisation in Australians with Bronchiectasis: A report of linked data from the Australian Bronchiectasis Registry.
7Catherine RungeCatherine Runge035Respiratory vaccination practices and infection experiences of Australian adults living with bronchiectasis
8Michal ShteinbergMichal Shteinberg036Adults with paediatric-onset bronchiectasis (POBE) have greater disease severity compared to those with adult-onset bronchiectasis (AOBE): A multicenter EMBARC registry study
9Lidia PereaOriol Sibila037The frequent exacerbator phenotype in bronchiectasis revisited: Data from the European Bronchiectasis Registry (EMBARC)
10George SolomonChristina Thornton038The Impact of Proton Pump Inhibitor (PPI) Use on Exacerbation Rates in Patients with Bronchiectasis: An Analysis of the US Bronchiectasis and NTM Research Registry

 
 

Session 5: Infections

Chairs: Gregory Tino (USA) – Doreen Addrizzo-Harris (USA)

Search :
#PresenterFirst AuthorDayAbs #Title
1Qaiser AkramQaiser Akram039Isolation of Multidrug Resistant Bacteria from hospitalized Bronchiectasis patients in Developing Countries
2Ophir Bar-OnOphir Bar-On040The Impact of Nebulised Fucose/Galactose on Pseudomonas aeruginosa Airway Infection
3Angelou CastroAngelou Castro041Respiratory viral pathogens during exacerbation of airway disease among adult Aboriginal Australians with bronchiectasis in the Top End Northern Territory Australia
4Timothy HowarthTimothy Howarth042Sputum antibacterial sensitivity and resistance patterns among adult Aboriginal Australians with Bronchiectasis in the Top End Northern Territory Australia
5Debora KidanuDebora Kidanu043Non-Cystic Fibrosis Bronchiectasis: Clinical Experience from Gold Coast University Hospital
6Emma LedgerEmma Ledger044A paradoxical role of antibodies driving complement-mediated inflammation in Pseudomonas aeruginosa pulmonary infections
7Arjuman SharminArjuman Sharmin045Microbiological profile of sputum cultures in patients with severe bronchiectasis: a cross-sectional study
8Kellie StricklandKellie Strickland047Population diversity and antimicrobial resistance profiling of Pseudomonas aeruginosa isolated from Australians with bronchiectasis
9Joshua TavernerJoshua Taverner048Systematic review of clinical practice guidelines to identify vaccination recommendations for adults living with chronic lung disease
10Harry ThompsonHarry Thompson049Pushing the boundaries of virtual wards? Medication regimes traditionally considered high risk for home administration delivered safely via a virtual ward, and the potentially under-considered trauma of long inpatient stays
11Kazuya ToneKazuya Tone050Pulmonary nocardiosis with a nodular-bronchiectatic pattern: A potential cause and aggravator of bronchiectasis

 
 

Session 6: NTM 1

Chairs: Stefano Aliberti (Italy) – Kozo Morimoto (Japan)

Search :
#PresenterFirst AuthorDayAbs #Title
1Hind Al-AbbasiHind Al-Abbasi051The impact of the introduction of the Cepheid Xpert MTB/XDR on mycobacterium tuberculosis clinical management in Western Australia
2Melinda M AshcroftMelinda M Ashcroft052The rising incidence of nontuberculous mycobacterial infections in First Nations People in Queensland, Australia 2001–2024.
3Desilia AtikawatiDesilia Atikawati053Nontuberculous Mycobacterial Pleuritis in Congestive Heart Failure and Hypothyroid Patient
4Atsushi FunauchiAtsushi Funauchi054Strain-Level Concordance Between Gastric Aspirate and Sputum Samples in Pulmonary Non-Tuberculous Mycobacterial Disease: A Retrospective Analysis
5Kazuki HashimotoKazuki Hashimoto055Rapid and Comprehensive Identification of Nontuberculous Mycobacteria from Sputum: NALC-Seq
6Shaun KangShaun Kang056Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease
7Daisy LuDaisy Lu057Epidemiology and clinical significance of NTM isolates at a tertiary centre in Victoria, Australia.
8Eriko MorinoEriko Morino058Pulmonary NTM epidemiology in Japan-Analysis of Medical Claim from National Database 2012-2019
9Kirby Patterson-FahyKirby Patterson-Fahy059In vitro efficacy of sulbactam-durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
10Dorothy Hui Lin NgDorothy Hui Lin Ng060Supportive Care Gaps in Bronchiectasis Patients with NTM-PD: A Retrospective Study
11Kazuki OnoKazuki Ono061Characteristics and Prognosis in Patients with Bronchiectasis Receiving Long-Term Oxygen Therapy
12Jotam G. PasipanodyaJotam G. Pasipanodya062Role of Rifampin in the treatment of Pulmonary Mycobacterium avian Complex disease: a systematic review and analyses of target attainment

 
 

 
 

Wednesday, 16th July 2025 from 18.00 to 19.00

Session 7: Microbiota

Chairs: Sanjay Chotirmall (India) – Steven Taylor (USA)

Search :
#PresenterFirst AuthorDayAbs #Title
1Tim BairdTim Baird101Using Meta-Omics to Advance Precision-Based Bronchiectasis Management
2Ria ThompsonRia Thompson102Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease
3Park JinkyeongPark Jinkyeong103Bacterial Profiles in Inhaler Devices after 30 Days of Use by Patients with Non-Cystic Fibrosis Bronchiectasis
4Arjuman SharminArjuman Sharmin104Sputum microbiology in severe bronchiectasis: A cross-sectional study
5Wen-Wen WangWen-Wen Wang105Pseudomonas aeruginosa-Driven Airway Dysbiosis and Machine Learning Prediction of Acute Exacerbations in Non-Cystic Fibrosis Bronchiectasis
6Kazuma YagiKazuma Yagi107The Impact of Microbiome on the Pathophysiology following Early-life Respiratory Syncytial Virus Infection

 
 

Session 8: NTM 2

Chairs: Jae-Joon Yim (South Korea) – Charles Daley (USA)

Search :
#PresenterFirst AuthorDayAbs #Title
1Stephanie SutjiptoStephanie Sutjipto108Management of Refractory Pulmonary Mycobacterium abscessus Infection in a Patient with Bronchiectasis: A Case Experience
2Shera TanShera Tan109A case of Disseminated Mycobacterium Kansasii Infection with Interferon-ÉŁ Auto-antibodies
3Heeral ThakkarHeeral Thakkar110Tigecycline Rechallenge for Pulmonary Mycobacterium abscessus Infection Following Hemorrhagic Pancreatitis: A Case Report
4Kirby Patterson-FahyKirby Patterson-Fahy111Does lignocaine effect growth of nontuberculous mycobacteria?
5Fumiya WatanabeFumiya Watanabe112A pharmacokinetic-pharmacodynamic modeling approach to optimize ethambutol dosage based on in vitro time-kill assay against Mycobacterium avium
6Adrifen Berti AkbarAdrifen Berti Akbar113Concurrent Malignant Pleural Mesothelioma with Pulmonary-Pleural Effusion Due to Non-Tuberculous Mycobacteria (NTM); a Rare Case Report
7Daniel HicksDaniel Hicks114Adverse events leading to Treatment Withdrawal and Interruption in Mycobacteroides abscessus pulmonary disease
8Hyung-Jun KimSeyoung Jung115Clinical Significance of Discordant ESR and CRP Levels in Nontuberculous Mycobacterial Pulmonary Disease
9Youngmok ParkJihoon Kim116Adverse Drug Reactions During the Treatment of Nontuberculous Mycobacterial Pulmonary Disease: a Systematic Review and Meta-analysis

 
 

Session 9: Paediatric

Chairs: Ahmad kantar (Italy) – Bernadette Prentice (Australia)

Search :
#PresenterFirst AuthorDayAbs #Title
1Alana AinsworthAlana Ainsworth117Prospective ten year follow-up of an early intervention versus control study for children with severe bronchiolitis or pneumonia.
2Crystal BourkeCrystal Bourke118Lung clearance index is more sensitive than spirometry to detect lung function impairment in children and adolescents with bronchiectasis
3Patrick A. FlumePatrick A. Flume119Incidence and potential underlying aetiologies of paediatric bronchiectasis in the US: 2018–2022
4Catherine A. GilchristCatherine A. Gilchrist120BRONCHIECTASIS EXACERBATIONS IN CHILDREN: CAN HOSPITAL STAYS BE SHORTER?
5Grace Hendriks, Jordan TrunfioGrace Hendriks121Bringing physiotherapy to First Nations children with chronic lung conditions in remote NT communities.
6Victoria IronsVictoria Irons122Are we prescribing the correct antibiotics for positive respiratory cultures from our children with bronchiectasis?
7Miriam MangaMiriam Manga123Koira4Rukahukahu: Lungs4Life: The development of a preventive program for chronic respiratory disease.
8Hannah O'FarrellHannah O'Farrell124Gene expression profiling of peripheral blood identifies systemic T-cell and neutrophilic immune response in paediatric bronchiectasis
9Laura RensfordLaura Rensford125Physical Activity Levels in Children with Bronchiectasis Living in Counties Manukau, New Zealand.
10Katherine RoseKatherine Rose126Are we completing the recommended first-line investigations for children with bronchiectasis at Starship Hospital?

 
 

Session 10: PCD

Chairs: Claire Hogg (UK) – Catherine Byrnes (New Zealand)

Search :
#PresenterFirst AuthorDayAbs #Title
1Megan FrohlichMegan Frohlich127Seeing the Unseen: Regional Lung Function Assessment in PCD and non-PCD Bronchiectasis using a Novel XV Scanner
2Gil HerzbergMoshe Heching128Use of rhDNase in Primary Ciliary Dyskinesia Bronchiectasis
3Stephanie MarchStephanie March129From the Paddock to the Hospital Room: Raising a Child with Primary Ciliary Dyskinesia in Rural Australia
4Caitlin MeechanCaitlin Meechan130Optimising Primary Ciliary Dyskinesia Screening in Adult Bronchiectasis. The value of nasal Nitric Oxide and PICADAR scoring.
5Felix C. RingshausenFelix C. Ringshausen131Creating evidence for the use of HypErtonic saLine in People with Primary Ciliary Dyskinesia – the multicenter, randomized, double-blind, crossover proof-of-concept clinical trial HELP-PCD

 
 

Session 11: Physiotherapy & Allied Healthcare

Chairs: Rebecca Keating (Australia) – Annemarie Lee (Australia)

Search :
#PresenterFirst AuthorDayAbs #Title
1Shereen Sharafaddin AlemamShereen Sharafaddin Alemam132Effectiveness of Airway Clearance Techniques in Bronchiectasis Management
2George M. SolomonChristina Feir133High frequency chest wall oscillation (HFCWO) data in the Bronchiectasis and Nontuberculous Mycobacteria (NTM) Research Registry (BRR)
3Carly TurnerCarly Turner134Feasibility of Electrical Impedance Tomography in assessing short-term effects of airway clearance techniques in adults with bronchiectasis, an observational study
4Tamara LazzarinTamara Lazzarin135Healthcare access for children with bronchiectasis across an expansive geographical area: Analysis of inclusive paediatric physiotherapy service across metropolitan, regional and remote Queensland.
5Anmol Kaur Manjit SinghAnmol Kaur Manjit Singh136Pulmonary Rehabilitation in Chronic Bronchiectasis: A Case Report on Sustained Improvements Through Individualized Therapy
6Jennifer PhillipsJennifer Phillips137Active cycle of breathing technique, oscillating-PEP therapy or walking with huffing during a bronchiectasis exacerbation
7Mitchell TaylorMitchell Taylor138Effectiveness of a stepwise model of airway clearance techniques in bronchiectasis: a prospective cohort study
8Carly TurnerCarly Turner139Web-based resources for healthcare professionals and individuals with bronchiectasis: A scoping review
9Elizabeth WebbElizabeth Webb140Exploring the barriers and enablers of airway clearance therapy and exercise amongst adults with bronchiectasis: a patient perspective

 
 

Session 12: Treatments and New Drugs

Chairs: Lucy Morgan (Australia) – Jennifer Pollock (UK)

Search :
#PresenterFirst AuthorDayAbs #Title
1Tim BairdSushil Agwan141Efficacy, Safety, Cost and Antimicrobial Resistance Potential of Long-term Inhaled Colistimethate Sodium in Bronchiectasis: A Real-World Regional Australian Single-Centre Experience
2Timothy AksamitTimothy Aksamit142Lung Function in Patients With Non-Cystic Fibrosis Bronchiectasis By Prespecified Subgroups in the Phase 3, Randomized, Double-Blind, Placebo-Controlled Aspen Trial
3Aowen ZhuangGary P. Anderson143Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases
4Julia BashfordJulia Bashford144CERTAIN Study: Ceftolozane/tazobactam continuous infusion for outpatient treatment of exacerbations of Cystic Fibrosis and Bronchiectasis
5William FlowersHarriet Caterson145Reducing the treatment burden for people with bronchiectasis: a protocol for deprescribing inhaled corticosteroids
6James ChalmersJames Chalmers146Efficacy of Brensocatib in Patients with Eosinophilic Inflammation in Bronchiectasis: An Analysis of the ASPEN Trial
7James D. ChalmersJames D. Chalmers147Results from a Phase II study (AIRLEAF®) of the dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in adults with bronchiectasis
8Presanth Nair JanathananPresanth Nair Janathanan148Barriers to Guideline-Directed Therapy for Stable Non- Cystic Fibrosis Bronchiectasis in Australia and New Zealand: A Narrative Review
9Kughanishah JeyabalanKughanishah Jeyabalan149From Exacerbations to Relief: Harnessing Biologics in the Dual Challenge of Severe Asthma and Bronchiectasis
10Xue-shan LiXue-shan Li150Bacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis
11James D. ChalmersJames D. Chalmers151Study design of a Phase III study (AIRTIVITY®) of the novel dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in people with bronchiectasis
12Katie RiceKatie Rice152Impact of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on bone density in patients with Cystic Fibrosis: a retrospective study.
13George SolomonGeorge Solomon153Initial assessment of the “Chronic Airways Assessment Test” (CAAT™) as a drug development tool in bronchiectasis

 
 

Session 13: Rising Stars & Oral Presenters

Search :
#PresenterFirst AuthorDayAbs #Title
1Michal ShteinbergMarcus A. Mall201A Phase II study (CLAIRAFLY®) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in adults with cystic fibrosis bronchiectasis
2Laura CooperLaura Cooper202Economic evaluation of a physiotherapy-led community-based airway clearance service for people with chronic lung conditions: single group interrupted time series
3James D. ChalmersDamian G. Downey203Safety and efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: Phase 1 results and Phase 2b trial design
4Robert FlowersRobert Flowers204Racial and Ethnic Disparities in Bronchiectasis Outcomes in an Urban Safety-Net Hospital
5Kiyoharu FukushimaKiyoharu Fukushima205Molecular Epidemiological Surveillance for Non-Tuberculous Mycobacterial Pulmonary Disease: A Single Center Prospective Cohort Study.
6Koji FuruuchiKoji Furuuchi206Gene Expression Profiling of Airway Epithelium in Mycobacterium avium Complex Lung Disease
7Rebecca HullRebecca Hull207Airway Interleukin-7 is a biomarker of exacerbation risk in patients with Pseudomonas aeruginosa infection in bronchiectasis
8Merete B LongMerete B Long208Results from the GREAT-2 phase II randomised placebo-controlled trial of the bispecific monoclonal antibody gremubamab targeting Pseudomonas aeruginosa in people with bronchiectasis
9Ellie MaasEllie Maas209Exome sequencing in a large cohort of primary ciliary dyskinesia: comprehensive evaluation of known genes and identification of new potential candidates
10Francesca NicolaFrancesca Nicola210Unraveling the pathogenicity of Mycobacterium abscessus in cystic fibrosis pulmonary epithelial cells and mouse models of respiratory infection.
11Lidia PereaLidia Perea211CC16 as a biomarker of bronchial infection and disease severity in bronchiectasis
12Jack RobertsJack Roberts212Development and validation of a bronchiectasis child-specific quality of life instrument: The BC-QoL
13Sarah WalkerSarah Walker213Alpha-1 Antitrypsin Deficiency and Asthma: Modelling a Candidate Bronchiectasis Risk Nexus
14Le-Le WangLe-Le Wang214Factors associated with hemoptysis in patients with non-cystic fibrosis bronchiectasis: cross-sectional analysis of data from the BE-China Registry
15Yingzhou XieYingzhou Xie215Identification of a Response Regulator Controlling Antibiotic Persister Formation in Pseudomonas aeruginosa
16Gary P. AndersonAowen Zhuang216Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases

 
 

 
 

We use cookies to ensure that we give you the best experience on our website.We use cookies to improve analyze its performance. You can authorize or block the cookies by clicking the checkbox on the right side of each single cookie. See our cookies policy.
Google Analytics, I accept:

We need your voice! Are you a clinician, researcher, allied health pro, or affected by bronchiectasis?
Help shape global research priorities.

Days
Hours
Minutes